Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zavicefta

- PMLiVE

Pfizer spins out SpringWorks Therapeutics biotech

Former Pfizer VP Lara Sullivan takes the helm at the newly-formed company

- PMLiVE

Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Germany and the UK will be the first to receive the skin cancer treatment

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

FDA clears Pfizer’s leukaemia drug Besponsa

The breakthrough treatment is the first CD22-targeted ADC to be approved in the US

- PMLiVE

How to keep your name development on schedule after the recent EMA NRG announcement

Three key action points

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

- PMLiVE

Xtandi slowdown weighs on Pfizer, but CEO won’t move on M&A

Investors call on the pharma giant to consider a large merger or acquisition deal

A healthcare landscape going through seismic change

Pfizer’s quest to generate health innovation as an ageing demographic threatens society’s ability to treat people

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links